260 related articles for article (PubMed ID: 28718801)
1. From Variation of Influenza Viral Proteins to Vaccine Development.
Zhu W; Wang C; Wang BZ
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28718801
[TBL] [Abstract][Full Text] [Related]
2. Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia.
Swayne DE; Suarez DL; Spackman E; Jadhao S; Dauphin G; Kim-Torchetti M; McGrane J; Weaver J; Daniels P; Wong F; Selleck P; Wiyono A; Indriani R; Yupiana Y; Sawitri Siregar E; Prajitno T; Smith D; Fouchier R
J Virol; 2015 Apr; 89(7):3746-62. PubMed ID: 25609805
[TBL] [Abstract][Full Text] [Related]
3. Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.
Kamlangdee A; Kingstad-Bakke B; Osorio JE
J Virol; 2016 Aug; 90(15):6771-6783. PubMed ID: 27194759
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
[TBL] [Abstract][Full Text] [Related]
5. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
[TBL] [Abstract][Full Text] [Related]
6. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
7. M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.
Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
Vaccine; 2017 Jul; 35(33):4177-4183. PubMed ID: 28668565
[TBL] [Abstract][Full Text] [Related]
8. An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.
Leung HC; Chan CC; Poon VK; Zhao HJ; Cheung CY; Ng F; Huang JD; Zheng BJ
Emerg Microbes Infect; 2015 Apr; 4(4):e22. PubMed ID: 26038770
[TBL] [Abstract][Full Text] [Related]
9. 220 mutation in the hemagglutinin of avian influenza A (H7N9) virus alters antigenicity during vaccine strain development.
Liu L; Lu J; Li Z; Zhou J; Guo J; Li X; Liu J; Shu Y; Wang D
Hum Vaccin Immunother; 2018 Mar; 14(3):532-539. PubMed ID: 29300686
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and protective efficacy of cold-adapted X-31 live attenuated pre-pandemic H5N1 influenza vaccines.
Jang YH; Jung EJ; Byun YH; Lee KH; Lee EY; Lee YJ; Seong BL
Vaccine; 2013 Jul; 31(33):3339-46. PubMed ID: 23742997
[TBL] [Abstract][Full Text] [Related]
11. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
[TBL] [Abstract][Full Text] [Related]
12. [Research progress and prospect of universal influenza vaccine].
Luo DY; Xue CY; Cao YC
Bing Du Xue Bao; 2013 Nov; 29(6):646-50. PubMed ID: 24520771
[TBL] [Abstract][Full Text] [Related]
13. Hemagglutinin amino acids related to receptor specificity could affect the protection efficacy of H5N1 and H7N9 avian influenza virus vaccines in mice.
Xu L; Bao L; Lau SY; Wu WL; Yuan J; Gu S; Li F; Lv Q; Xu Y; Pushko P; Chen H; Qin C
Vaccine; 2016 May; 34(23):2627-33. PubMed ID: 27083426
[TBL] [Abstract][Full Text] [Related]
14. Progress on adenovirus-vectored universal influenza vaccines.
Xiang K; Ying G; Yan Z; Shanshan Y; Lei Z; Hongjun L; Maosheng S
Hum Vaccin Immunother; 2015; 11(5):1209-22. PubMed ID: 25876176
[TBL] [Abstract][Full Text] [Related]
15. Vaccine approaches conferring cross-protection against influenza viruses.
Vemula SV; Sayedahmed EE; Sambhara S; Mittal SK
Expert Rev Vaccines; 2017 Nov; 16(11):1141-1154. PubMed ID: 28925296
[TBL] [Abstract][Full Text] [Related]
16. Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge.
Park KS; Lee J; Ahn SS; Byun YH; Seong BL; Baek YH; Song MS; Choi YK; Na YJ; Hwang I; Sung YC; Lee CG
Virology; 2009 Dec; 395(2):182-9. PubMed ID: 19836045
[TBL] [Abstract][Full Text] [Related]
17. Experimental challenge of chicken vaccinated with commercially available H5 vaccines reveals loss of protection to some highly pathogenic avian influenza H5N1 strains circulating in Hong Kong/China.
Connie Leung YH; Luk G; Sia SF; Wu YO; Ho CK; Chow KC; Tang SC; Guan Y; Malik Peiris JS
Vaccine; 2013 Aug; 31(35):3536-42. PubMed ID: 23791547
[TBL] [Abstract][Full Text] [Related]
18. Emerging influenza viruses and the prospect of a universal influenza virus vaccine.
Krammer F
Biotechnol J; 2015 May; 10(5):690-701. PubMed ID: 25728134
[TBL] [Abstract][Full Text] [Related]
19. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
Itoh Y; Ozaki H; Tsuchiya H; Okamoto K; Torii R; Sakoda Y; Kawaoka Y; Ogasawara K; Kida H
Vaccine; 2008 Jan; 26(4):562-72. PubMed ID: 18164788
[TBL] [Abstract][Full Text] [Related]
20. A new generation of modified live-attenuated avian influenza viruses using a two-strategy combination as potential vaccine candidates.
Song H; Nieto GR; Perez DR
J Virol; 2007 Sep; 81(17):9238-48. PubMed ID: 17596317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
